Supplemental Table 1 from Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1. Adverse events observed and adjudicated as possibly, probably or definitely related to therapy (n = 19).
Authors: Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361912686